Prevalence and prognostic value of cutaneous manifestations in patients with myelodysplastic syndrome

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 10, 2010, Pages 1171-1175

  Farah, C ^a   Bulai Livideanu, C ^a   Jegu, J ^a   Paul, C ^a   Viraben, R ^a   Lamant, L ^a   Delavigne, K ^a   Adoue, D ^a   Laurent, G ^a   Beyne Rauzy, O ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

cohort study; leucocytoclastic vasculitis; myelodysplastic syndrome; neutrophilic dermatosis

Indexed keywords

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BEHCET DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; LEUKOCYTOCLASTIC VASCULITIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MEDICAL EXAMINATION; MYELODYSPLASTIC SYNDROME; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SKIN DISEASE; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; SURVIVAL; VASCULITIS;

ADULT; AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN DISEASES;

EID: 77956301773     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03614.x     Document Type: Article

References (11)

1. Mufti G. Pathobiology, classification and diagnosis of myelodysplastic syndrome. Best Pract Res 2004 4 : 543 557.
2. Beyne-Rauzy O, Laurent G, Adoue D. Syndromes myelodysplasiques de l'adulte. Presse Med 2007 36 : 481 491.
3. Mufti G, Chen T. Changing the treatment paradigm in myelodysplastic syndromes. Cancer Control 2008 15 : 14 28.
4. Aractingi S, Bachmeyer C, Miclea JM et al. Unusual specific cutaneous lesions in myelodysplastic syndromes. J Am Acad Dermatol 1995 33 : 187 189.
5. Avivi I, Rosenbaum H, Levy Y, Rowe J. Myelodysplastic syndrome and associated skin lesions: a review of the literature. Leuk Res 1999 23 : 323 330.
6. Dalamaga M, Karmaniolas K, Matekovits A et al. Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients. J Eur Acad Dermatol Venereol 2008 22 : 543 548.
7. Lin YC, Liang TH, Chang HN et al. Behcet disease associated with myelodysplastic syndrome. J Clin Rheumatol 2008 14 : 169 174.
8. Longrace TA, Smoller BR. Leukemia cutis, analysis of 50 proven cases with an emphasis on occurrence in myelodysplastic syndromes. Am J Clin Pathol 1993 100 : 276 284.
9. Aractingi S, Bachmeyer C, Dombret H et al. Simultaneous occurrence of two rare cutaneous markers of poor prognosis in myelodysplastic syndrome: erythema elevatum diutinum and specific lesions. Br J Dermatol 1994 131 : 112 117.
10. Evans AV, Sabroe RA, Liddell K, Russell-Jones R. Lymphocytic infiltrates as a presenting features of Sweet's syndrome with myelodysplasia and response to cyclophosphamide. Br J Dermatol 2002 146 : 1087 1090.
11. Browning CE, Dixon JE, Malone JC, Callen JP. Thalidomide in the treatment of recalcitrant Sweet's Syndrome associated with myelodysplasia. J Am Acad Dermatol 2005 53 : 135 138.